Quantcast

Latest Lilly Stories

2014-06-09 08:30:07

Company to highlight late-stage pipeline molecules, including once-weekly dulaglutide and basal insulin peglispro INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced 76 abstracts to be presented June 13-17 at the 74(th) American Diabetes Association Scientific Sessions(®) in San Francisco, highlighting the company's long-standing commitment to advancing scientific knowledge in the field of diabetes management. Forty-three of these abstracts will be...

2014-06-09 08:29:57

· Data for investigational compounds LY2963016, empagliflozin and empagliflozin/linagliptin combination tablet highlight robust alliance pipeline RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and Company (NYSE: LLY) diabetes portfolio at the 74(th) American Diabetes Association (ADA) Scientific Sessions® in San Francisco, June 13-17....

2014-06-05 16:22:51

-- System is one of the largest for a pharmaceutical company worldwide, the largest for a pharmaceutical company in New Jersey -- BEDMINSTER, N.J., June 5, 2014 /PRNewswire/ -- KDC Solar LLC has commenced commercial operations of its 9.95-megawatt (MW) solar panel system in New Jersey. The system will provide electricity to Eli Lilly and Company's ImClone biopharmaceutical operations in Branchburg, N.J. Lilly acquired ImClone Systems in 2008....

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-06-02 08:26:14

INDIANAPOLIS, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and...

2014-05-30 04:22:13

HILDEN, Germany, and GERMANTOWN, Maryland, May 30, 2014 /PRNewswire/ -- - Fourth oncology project with Lilly expands QIAGEN's Personalized Healthcare pipeline - Development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with innovative cancer therapies under development by Lilly - Project to include assays for QIAGEN's new multi-modal, multi-analyte Modaplex...

2014-05-28 08:30:29

Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED). Under the terms of the...

2014-05-27 16:25:01

INDIANAPOLIS, May 27, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 16 for the media and investment community to provide detailed updates for dulaglutide, its investigational glucagon-like receptor agonist (GLP-1) being studied for the treatment of type 2 diabetes. The call, which is being held in conjunction with the 74(th )American Diabetes Association Scientific Sessions, will include updates on Phase III data for dulaglutide,...

2014-05-22 16:26:51

INDIANAPOLIS, May 22, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 30(th) Annual Sanford C. Bernstein Strategic Decisions Conference on Wednesday, May 28, 2014. John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer, will participate in a fireside chat at 3:00 p.m. EDT. A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm....

2014-05-16 23:06:45

Study looks at Panama and Miami as ideal distribution hub to Latin America. Miami, FL (PRWEB) May 16, 2014 Florida International University (FIU) Masters of International Business (MIB) students and international freight forwarder LILLY + Associates International released a semester-long study weighing the benefits between PortMiami and Panama as the natural distribution hub for the Americas. "The meticulous level of work performed by the FIU MIB students, under the direction of...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related